Insider Trading July 8, 2026 05:03 PM

SenesTech Chief Executive Officer Executes Share Purchase Amid Stock Valuation Review

CEO Michael Edell acquires 1,000 shares as SenesTech reports Q1 revenue growth and strategic market expansion

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
SNES

SenesTech Inc. (NASDAQ: SNES) Chief Executive Officer Michael Edell completed a direct purchase of 1,000 shares on July 7, 2026, bringing his total direct holdings to 5,000 shares. The transaction occurred at $1.4299 per share, totaling $1,429. This acquisition follows a period where SNES shares traded near $1.38, reflecting a 72% decline over the past year. Recent corporate developments include a 2% revenue increase in Q1 2026, a record gross margin expansion, a new executive appointment, and a strategic distribution agreement in Bermuda. SenesTech also adjusted its share increase request under the 2018 Equity Incentive Plan ahead of its annual meeting.

SenesTech Chief Executive Officer Executes Share Purchase Amid Stock Valuation Review
SNES
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Michael Edell acquired 1,000 shares at $1.4299 per share, bringing his total direct holdings to 5,000 shares.
  • SenesTech reported a 2% revenue increase to $493,000 in Q1 2026 and achieved a record gross margin of 68.6%.
  • The company expanded its market reach through a distribution agreement in Bermuda and appointed Jack Karabees as Executive Vice President of Sales.

Michael Edell, serving as Chief Executive Officer of SenesTech Inc. (NASDAQ: SNES), executed a direct acquisition of 1,000 shares of the company’s common stock on July 7, 2026, as documented in a recent regulatory filing. The transaction was settled at a price of $1.4299 per share, resulting in a total investment value of $1,429. Following this purchase, Edell’s direct ownership position in SenesTech common stock stands at 5,000 shares.

The timing of this acquisition aligns with SNES trading near $1.38, a level that reflects a 72% decline over the past year and positions the stock close to its 52-week low. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the platform’s Most Undervalued list. For deeper insights, investors can access the comprehensive Pro Research Report, available for SNES and 1,400+ US equities.

In other recent news, SenesTech Inc. reported a 2% increase in revenue for the first quarter of 2026, totaling $493,000 compared to $485,000 in the same period the previous year. The company also achieved a record gross margin of 68.6%, up from 64.5% in Q1 2025. In corporate developments, SenesTech appointed Jack Karabees as Executive Vice President of Sales, bringing over 30 years of B2B sales experience to the team. Additionally, SenesTech expanded its market reach by entering into a distribution agreement with Animal and Garden House to offer its Evolve Rodent Birth Control products in Bermuda. This move comes as traditional rodenticides face regulatory restrictions in the region due to environmental concerns. Furthermore, the company announced a reduction in its share increase request under the 2018 Equity Incentive Plan from 1.7 million shares to 1.2 million shares, which will be presented for stockholder approval at the upcoming annual meeting. These recent developments reflect SenesTech’s ongoing efforts in market expansion and corporate governance.

Key Points

  • CEO Share Acquisition: Michael Edell purchased 1,000 shares at $1.4299 per share, bringing his total direct holdings to 5,000 shares.
  • Financial Performance: Q1 2026 revenue increased by 2% to $493,000, with a record gross margin of 68.6%.
  • Strategic Expansion: New distribution agreement in Bermuda and appointment of Jack Karabees as Executive Vice President of Sales.

Risks and Uncertainties

  • Stock Price Volatility: SNES has declined 72% over the past year and trades near its 52-week low, indicating potential market sensitivity.
  • Regulatory Environment: Traditional rodenticides face regulatory restrictions in Bermuda, which may impact the adoption of alternative products.
  • Shareholder Approval: The reduced share increase request under the 2018 Equity Incentive Plan requires stockholder approval at the upcoming annual meeting, introducing governance uncertainty.

Risks

  • SNES stock has declined 72% over the past year and trades near its 52-week low, indicating potential market volatility.
  • Traditional rodenticides face regulatory restrictions in Bermuda, which may impact the adoption of alternative products.
  • The reduced share increase request under the 2018 Equity Incentive Plan requires stockholder approval, introducing governance uncertainty.

More from Insider Trading

Sezzle CFO Executes Pre-Arranged Sale Amid Stock Surge Jul 8, 2026 Symbotic Director Todd Krasnow Executes Stock Sales Amid Volatile Trading Period Jul 8, 2026 Stitch Fix CFO David Aufderhaar Executes $257,432 Share Disposition Under Pre-Arranged Plan Jul 8, 2026 Stitch Fix CPTO Bacos Executes $265K Share Sale Under Pre-Arranged Plan Jul 8, 2026 Indie Semiconductor COO Michael Wittmann Executes $29,213 Stock Sale Under Pre-Arranged Trading Plan Jul 8, 2026